Docetaxel in Castration-Resistant Prostate Cancer: A Single-Centre Experience

作者：Beatrice Detti; Davide Franceschini^*; Calogero Saieva; Lucia Di Brina; Mohammed Baki; Icro Meattini; Vanessa Di Cataldo; Eleonora Monteleone Pasquetti; Ilaria Furfaro; Anna Mancuso; Gabriele Simontacchi; Lorenzo Livi

来源：Cancer Investigation, 2014, 32(9): 445-450.

DOI：10.3109/07357907.2014.958233

• Therapy
• Chemotherapy
• Bladder
• Prostate cancer

We present a single-institution experience reporting the efficacy and safety of docetaxel, administered as first-line chemotherapy, in castration-resistant prostate cancer (CRPC), focusing on patients and treatment parameters. From November 2004 to January 2012, 51 patients received chemotherapy with docetaxel. With a mean follow-up time (from the beginning of CHT) of 1.6 years (range 0.1-5.1 years), 35 patients (68.6%) died for prostate cancer and 48 patients (94.1%) showed progression of the disease. Five factors influenced overall survival: nodal status at diagnosis, neoadjuvant hormonal therapy, number of cycles of docetaxel administered, schedule of docetaxel and ECOG performance status before starting chemotherapy.

• 出版日期2014-10